8 Peptides Being Studied for Women's Hormonal and Metabolic Health in 2026

Peptide research has moved well beyond the fitness forums where most people first encountered the term. In 2026, an expanding body of clinical evidence is examining how specific peptides interact with the hormonal and metabolic systems that disproportionately affect women — particularly those navigating PCOS, perimenopause, insulin resistance, and thyroid dysfunction.

The conversation is overdue. For decades, most metabolic and endocrine trials enrolled predominantly male subjects, leaving women to extrapolate from biology that was never designed to map onto theirs. That gap is narrowing, and peptide science sits at the centre of some of the most targeted research currently in progress.

This article covers eight peptides with active or recent clinical research relevance for women's hormonal and metabolic health — the mechanism, the condition it addresses, the evidence standard, and the honest limitations. If you are new to this topic, start with Meto's foundational guide: What Are Peptides? A Beginner's Guide to Metabolic and Hormonal Health.

Why Peptides Are Relevant to Women's Hormonal Health

Peptides are short amino acid chains that function as signalling molecules — binding to specific receptors and triggering hormonal, metabolic, or immune responses downstream. What makes this relevant to women is the layered complexity of female hormonal biology. Estrogen, progesterone, LH, FSH, insulin, cortisol, and thyroid hormones interact across feedback loops that shift across a woman's reproductive lifespan. Peptides, by virtue of their receptor precision, offer researchers a way to probe — and potentially modulate — those loops without the blunt systemic effects of traditional hormonal therapies.

This is not a claim that peptide therapy replaces HRT, PCOS management, or standard metabolic care. It is context for why the research momentum exists. For a deeper breakdown of cellular mechanisms, see Meto's guide on how peptides work in the body.

The 8 Peptides

1. Kisspeptin

Primary focus: Reproductive axis regulation · PCOS · Menopause transition

Kisspeptin is a hypothalamic neuropeptide that sits at the top of the reproductive endocrine cascade. It stimulates GnRH release, which drives LH and FSH — the pituitary hormones governing ovulation and cycle regularity. Without adequate kisspeptin signalling, the hormonal axis falters.

Women with PCOS exhibit dysregulated kisspeptin activity — specifically, elevated early-follicular levels contributing to the excess LH drive characteristic of the condition. A 2014 study in the Journal of Clinical Investigation confirmed kisspeptin as the mediator of sex steroid negative feedback to the hypothalamus in women. In perimenopause, hyperactive kisspeptin neurons are now understood to drive vasomotor symptoms — hot flushes and night sweats — via co-expressed neurokinin B and dynorphin pathways. Multiple Phase II trials are currently examining kisspeptin analogues for both menopausal symptom control and ovulation induction. See ClinicalTrials.gov for active studies.

Status: Phase I/II trials · Not commercially available · SC/IV (research settings) · Not FDA-approved

Caveat: The mechanistic case is solid; reliable clinical protocols for diverse women's applications require considerably more trial data.

2. GLP-1 Agonist Peptides

Primary focus: Metabolic health · PCOS · Insulin resistance · Weight regulation

Of all the peptides on this list, GLP-1 receptor agonists are the furthest along in the evidence hierarchy — and the most consequential for women's metabolic health today. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved and widely prescribed, but their sex-specific mechanisms in hormonal disease are still being actively characterised.

In PCOS — where insulin resistance is present in up to 80% of affected women regardless of body weight — GLP-1 agonists have demonstrated measurable reductions in free testosterone, improved menstrual regularity, and significant metabolic benefit. A 2019 review in Hormone and Metabolic Research documented these outcomes, while the landmark STEP 1 trial (Wilding et al., NEJM 2021) established 14.9% average weight reduction with semaglutide — with direct relevance to androgen-driven conditions where adipose tissue is itself a hormonal organ.

Meto's clinical breakdown of how semaglutide and tirzepatide are reshaping metabolic medicine covers SURMOUNT-5 head-to-head data in full. If choosing between GLP-1 agents, your biology should lead: lab-guided GLP-1 selection explained here.

Status: FDA-approved (metabolic/weight indications) · Weekly SC injection · Available via prescription

Caveat: GLP-1 side effects — including liver, kidney, and pancreatic risks — are detectable early with proper lab monitoring. Testing before and during treatment is non-negotiable.

3. BPC-157

Primary focus: Gut-hormone axis · Systemic inflammation · Tissue repair

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a gastric protein. Its relevance to women's hormonal health is indirect: gut mucosal integrity and chronic low-grade inflammation are now recognised as meaningful modulators of hormonal function — particularly in PCOS, Hashimoto's thyroiditis, and perimenopause-associated metabolic disruption.

Animal studies from Sikiric et al. (Current Pharmaceutical Design, 2018) document cytoprotective effects on gastrointestinal tissue and modulation of dopamine and serotonin pathways. The core concern is the translation gap: the majority of BPC-157 research remains preclinical. Robust human RCT data is absent.

Status: Research phase · No completed human RCTs · Not FDA-approved · SC injection or oral (research only)

Caveat: BPC-157 is under review at the FDA's July 2026 peptide advisory panel and is currently restricted for compounding. Before engaging with any marketed source, read Meto's guide on research vs pharmaceutical-grade peptides.

4. PT-141 (Bremelanotide)

Primary focus: Female sexual dysfunction · Hypoactive Sexual Desire Disorder (HSDD)

PT-141 is the only peptide on this list with direct FDA approval for a women's health indication. Sold as Vyleesi, bremelanotide was approved in 2019 for premenopausal women with acquired, generalised HSDD — clinically defined as low sexual desire causing significant personal distress.

Unlike testosterone-based approaches, PT-141 acts centrally on melanocortin receptors (MC3R, MC4R) in the brain, influencing desire through dopaminergic pathways rather than peripheral blood flow. The RECONNECT trials (Simon et al., Obstetrics & Gynecology, 2019) demonstrated statistically significant improvement in desire scores and a meaningful reduction in distress versus placebo. Given that sexual dysfunction in women is frequently entangled with hormonal decline in perimenopause and androgen disruption in PCOS, this is a legitimate clinical tool — not a niche one.

Status: FDA-approved (HSDD in premenopausal women) · SC injection as-needed · Available via prescription

Caveat: Transient nausea, flushing, and blood pressure changes are common. Contraindicated in cardiovascular disease and with nitrate use.

5. CJC-1295 + Ipamorelin

Primary focus: Growth hormone support · Perimenopause · Body composition

CJC-1295 is a GHRH analogue; ipamorelin is a selective GH secretagogue. Together, they extend and amplify the pituitary's natural GH pulses — a mechanism with direct relevance to perimenopause, during which growth hormone declines sharply, accelerating visceral fat accumulation, muscle loss, and bone density reduction.

A 2006 study by Alba et al. in the Journal of Clinical Endocrinology and Metabolism confirmed that CJC-1295 produced sustained, dose-dependent GH elevation in healthy adults. The combination is used in clinical longevity and hormone optimisation practices, though rigorous sex-stratified RCT data in perimenopausal women specifically is still limited.

Status: Off-label clinical use · Not FDA-approved for these indications · Nightly SC injection

Caveat: GH secretagogues affect insulin sensitivity. Baseline IGF-1 and fasting insulin testing are essential. Meto's PCOS & Hormonal Health Panel includes the relevant baseline markers.

6. Thymosin Alpha-1

Primary focus: Autoimmune thyroid disease · Hashimoto's thyroiditis · Immune-hormonal axis

Thymosin Alpha-1 (Tα1) is a naturally occurring thymic peptide with well-documented immune-modulatory properties. Its relevance here stems from a clinical reality: autoimmune thyroid disease — primarily Hashimoto's — affects women at seven to ten times the rate of men, and is a leading cause of hypothyroidism, fatigue, weight gain, and menstrual irregularity in women aged 30–60.

Studied for decades in viral hepatitis and oncology (Goldstein et al., Expert Opinion on Biological Therapy, 2009), Tα1 is now being examined for its capacity to reduce the autoimmune T-cell response in Hashimoto's — with preliminary data suggesting potential reduction in TPO antibody levels. Human trials specific to autoimmune thyroid disease in women remain limited in scale.

Status: Approved in some countries for hepatitis · Off-label for immune modulation · SC injection

Caveat: Not a substitute for thyroid hormone replacement. Meto's Longevity Panel includes TSH, Free T3, Free T4, and thyroid antibodies — the right starting baseline for any thyroid discussion.

7. Epithalon

Primary focus: Pineal regulation · Melatonin · Biological aging · Menopause sleep disruption

Epithalon is a tetrapeptide (Ala-Glu-Asp-Gly) that mimics epithalamin, a peptide extract from the pineal gland. Its most documented property is the activation of telomerase — the enzyme that maintains telomere length and is associated with cellular longevity (Khavinson et al., Neuro Endocrinology Letters, 2003).

For women, the primary interest lies in its influence on melatonin secretion and circadian function — both of which decline markedly in menopause and contribute to the sleep disruption that compounds metabolic deterioration in this phase. Early studies suggest Epithalon may restore melatonin rhythmicity and reduce oxidative stress markers, though independent replication at scale is lacking.

Status: Research phase · Not FDA-approved · Predominantly Eastern European literature · SC injection or nasal spray

Caveat: Most research originates from a single group. Treat this as early-stage science — one to monitor, not yet to act on.

8. MOTS-c

Primary focus: Mitochondrial metabolism · Insulin sensitivity · Metabolic aging in women

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is encoded in mitochondrial DNA — not the nuclear genome — and functions as a mitochondrial-derived peptide that communicates metabolic stress signals systemically. Its discovery, published in Cell Metabolism (Lee et al., 2015), established it as a key regulator of glucose metabolism and insulin sensitivity.

Its relevance to women's health crystallised with the finding that MOTS-c levels decline with age and estrogen depletion — correlating directly with reduced skeletal muscle insulin sensitivity and visceral adiposity in postmenopausal women. A 2022 Cell Reports study (Kim et al.) confirmed sex-dimorphic expression, with distinct patterns and effects in women versus men. Notably, exercise robustly increases endogenous MOTS-c — one mechanism by which physical activity confers metabolic protection in aging women. Exogenous MOTS-c is now in early-phase human trials.

Status: Early-phase human trials · Not commercially available · SC injection (research settings)

Caveat: Strong mechanistic case. Clinical translation to dosing protocols and outcomes in women is still being established.

At-a-Glance Comparison

Frequently Asked Questions

Are peptides safe for women with hormonal imbalances? 

Safety depends entirely on the specific peptide, its source, dosage, and the individual's clinical profile. FDA-approved peptides (GLP-1 agonists, PT-141) have established safety data. Research-phase compounds carry inherently higher uncertainty. Lab-based baseline evaluation always comes first. Meto's guide on verifying peptide therapy safety covers the pre-treatment checklist.

Can peptides help with PCOS symptoms? 

GLP-1 agonists carry the strongest clinical evidence for PCOS — improving insulin sensitivity, reducing androgens, and supporting weight regulation. Kisspeptin is under study for ovulatory dysfunction specifically. Understanding your PCOS blood test results and knowing the seven signs that warrant PCOS testing are the necessary foundations before any therapeutic decision.

Is peptide therapy the same as hormone replacement therapy (HRT)? 

No. HRT directly replaces deficient hormones. Most peptides here modulate signalling pathways upstream of hormone production or address the metabolic consequences of hormonal disruption. They are not interchangeable, and the current evidence does not support using research peptides as a substitute for evidence-based HRT where HRT is clinically indicated.

Are any of these peptides FDA-approved specifically for women? 

Two: GLP-1 agonists (semaglutide, tirzepatide) for metabolic and weight indications, and bremelanotide (PT-141) for HSDD in premenopausal women. The remainder are in research or off-label use. For regulatory context on the FDA's 2026 peptide review, read Meto's breakdown of the July 2026 advisory meeting.

How do GLP-1 peptides affect women's hormones differently than men's? 

Women with PCOS or perimenopause respond through mechanisms that extend beyond weight loss — including direct reduction in ovarian androgen production and modulation of the LH/FSH ratio. These sex-specific pathways are an active research area and are why lab-guided GLP-1 selection matters considerably more than defaulting to whatever a friend is taking.

Meto's Take: What This Means for Women Seeking Answers

Women consistently arrive at Meto carrying a constellation of symptoms — persistent fatigue, weight shifts despite careful eating, irregular cycles, disrupted sleep, low libido — after being told their labs are "normal." The emerging peptide science is confirming what many of these women have already sensed: their endocrine and metabolic systems are under strain that standard screening does not capture.

At Meto, we do not prescribe peptide protocols outside established clinical evidence. What we provide is the thorough hormonal and metabolic evaluation that any evidence-based therapeutic conversation must be built upon. Your HOMA-IR, free testosterone, LH/FSH ratio, thyroid antibodies, fasting insulin, and estradiol trajectory are not optional background — they are the clinical foundation.

The PCOS & Hormonal Health Panel and Comprehensive Metabolic Panel are the right starting points. Your biology has a story. You should know what it says before anyone recommends an intervention.

Book a Women's Hormonal Health Consult at Meto

Our clinicians specialise in PCOS, perimenopause, menopause, insulin resistance, and thyroid dysfunction — with physician-led evaluation, personalised lab review, and treatment plans grounded in your actual biology. Most visits are covered by insurance, with an average patient copay of $0–$50.

Start Your Assessment →

Closing Note

GLP-1 agonists are changing clinical practice right now. Kisspeptin analogues and MOTS-c represent the frontier that will likely define the next decade of metabolic medicine for women. Compounds like BPC-157 and Epithalon require considerably more rigorous human data before earning a place in standard protocols. The most useful thing you can do with this information is bring it to a clinical conversation — not as a shopping list, but as a map of the terrain.

For the broader picture of where peptide therapy stands in medicine today: Peptide Therapy and Mainstream Medicine in 2026: The Evidence.

Medical disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, a diagnosis, or a treatment recommendation. Always consult a qualified clinician before considering any peptide therapy. 

This article was reviewed by Meto's clinical team. All external citations link to peer-reviewed publications or official regulatory sources. Last reviewed: May 2026.